Accepted for Publication: November 1, 2022.
Published Online: February 9, 2023. doi:10.1001/jamaoncol.2022.7173
Corresponding Author: Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy (filippo.pietrantonio@istitutotumori.mi.it).
Author Contributions: Drs Leone and Pietrantonio had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Leone, Trapani, Safer, Marsoni, Perrone, Cinieri, Pietrantonio.
Acquisition, analysis, or interpretation of data: Leone, Schabath, Scout, Lambertini, Berardi, Cinieri, Miceli, Morano, Pietrantonio.
Drafting of the manuscript: Leone, Trapani, Schabath, Marsoni, Cinieri, Miceli, Pietrantonio.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Trapani, Lambertini, Morano.
Supervision: Leone, Trapani, Safer, Berardi, Marsoni, Perrone, Cinieri, Miceli, Morano, Pietrantonio.
Conflict of Interest Disclosures: Dr Schabath reported receiving personal fees from Bristol Myers Squibb outside the submitted work. Dr Lambertini reported having an advisory role for and receiving speaker honoraria from Roche, Novartis, Eli Lilly & Company, and Pfizer; having an advisory role for AstraZeneca, MSD, Exact Sciences, and Seagen; receiving speaker honoraria from Takeda, Sandoz, Ipsen, Knight, Libbs, and Daiichi Sankyo; and having an advisory role for and receiving travel support and a research grant (to the institution) from Gilead outside the submitted work. Dr Berardi reported receiving personal fees from Amgen, MSD, Bristol Myers Squibb, Eisai, Roche, and AstraZeneca outside the submitted work. Dr Perrone reported receiving personal fees from Bayer, Roche, Incyte, Ipsen, AstraZeneca, Sanofi, Astellas, Eli Lilly & Company, GSK, Boeringher Ingelheim, and Pfizer outside the submitted work. Dr Cinieri reported receiving personal fees from Lilly Oncology, Seagen, and AstraZeneca outside the submitted work. Dr Morano reported receiving honoraria from Servier and Eli Lilly & Company, research grants from Incyte, and nonfinancial travel support from Daiichi Sankyo outside the submitted work. Dr Pietrantonio reported receiving grants from BMS, Incyte, and AstraZeneca and personal fees from BMS, MSD, AstraZeneca, Amgen, Merck Serono, Eli Lilly & Company, Pierre Fabre, Servier, Bayer, and Organon outside the submitted work. No other disclosures were reported.
Additional Contributions: The Italian Association of Medical Oncology and Elma Academy staff helped in reviewing the data